Screener
Maze Therapeutics MAZE CA — Tax Credit Carryforward Amount
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Maze Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:TaxCreditCarryforwardAmount.
The source filing: Maze Therapeutics’s 10-K, filed March 25, 2026.
- Filed
- Mar 25, 2026, 12:00 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001193125-26-122778
| Line item | December 31, 2025 | Expiration year |
|---|---|---|
| Net operating losses, federal (post-December 31, 2017) | $283,607 | Do not expire |
| Net operating losses, federal (pre-January 1, 2018) | — | 12/31/2037 |
| Net operating losses, state | 2,076 | 2037—2045 |
| Tax credits, federal | 15,362 | 2039—2045 |
| Tax credits, state (CA) | 10,867 | Do not expire |
| Tax credits, state (MA) | 235 | 2034-2038 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Maze Therapeutics's CA — tax credit carryforward amount?
- Maze Therapeutics (MAZE) reported CA — tax credit carryforward amount of $10.87M in Q4 2025.
- What does CA — tax credit carryforward amount mean?
- This metric represents the total value of tax credits generated in the California jurisdiction that have not yet been utilized to offset tax liabilities. These carryforwards serve as a potential future tax shield, reflecting the company's ability to reduce future cash tax outflows based on historical research and development or other qualifying activities. Investors monitor this balance to assess the company's potential for tax-efficient operations as it transitions toward commercialization.
Ask your AI about Maze Therapeutics's ca — tax credit carryforward amount.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude